Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatic Stellate Cells | 6 | 2025 | 23 | 3.800 |
Why?
|
| Liver Cirrhosis | 7 | 2025 | 163 | 3.570 |
Why?
|
| RNA, Long Noncoding | 4 | 2024 | 152 | 2.260 |
Why?
|
| Cell Differentiation | 14 | 2021 | 1304 | 1.770 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 170 | 1.620 |
Why?
|
| Embryonic Stem Cells | 5 | 2017 | 151 | 1.210 |
Why?
|
| Smad3 Protein | 3 | 2016 | 17 | 1.080 |
Why?
|
| Liver | 4 | 2025 | 795 | 1.070 |
Why?
|
| Fatty Liver | 2 | 2024 | 98 | 1.020 |
Why?
|
| Transcription Factors | 8 | 2023 | 1471 | 1.020 |
Why?
|
| Human Embryonic Stem Cells | 3 | 2020 | 35 | 0.960 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 152 | 0.910 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2024 | 15 | 0.900 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 91 | 0.900 |
Why?
|
| Transcriptome | 3 | 2025 | 340 | 0.880 |
Why?
|
| Hepatocytes | 1 | 2025 | 196 | 0.850 |
Why?
|
| Endoderm | 2 | 2020 | 45 | 0.820 |
Why?
|
| Cicatrix | 1 | 2022 | 59 | 0.760 |
Why?
|
| Collagen | 2 | 2022 | 115 | 0.720 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2022 | 33 | 0.700 |
Why?
|
| Phase Transition | 1 | 2020 | 20 | 0.700 |
Why?
|
| Adenosine | 2 | 2017 | 70 | 0.680 |
Why?
|
| Gene Expression Regulation | 8 | 2017 | 1552 | 0.640 |
Why?
|
| Genome, Human | 2 | 2020 | 224 | 0.640 |
Why?
|
| Signal Transduction | 10 | 2024 | 2903 | 0.630 |
Why?
|
| Histones | 2 | 2020 | 457 | 0.590 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 11 | 0.570 |
Why?
|
| Adult Stem Cells | 1 | 2017 | 28 | 0.560 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 19 | 0.560 |
Why?
|
| Ceramides | 1 | 2017 | 25 | 0.550 |
Why?
|
| Goosecoid Protein | 1 | 2016 | 4 | 0.540 |
Why?
|
| Myofibroblasts | 3 | 2025 | 15 | 0.510 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 147 | 0.470 |
Why?
|
| Mice | 18 | 2025 | 10294 | 0.460 |
Why?
|
| Collagen Type I | 2 | 2025 | 39 | 0.460 |
Why?
|
| Gene Expression Profiling | 3 | 2025 | 718 | 0.450 |
Why?
|
| RNA | 2 | 2017 | 401 | 0.450 |
Why?
|
| Interferon-gamma | 5 | 2024 | 551 | 0.450 |
Why?
|
| Smad2 Protein | 1 | 2014 | 8 | 0.450 |
Why?
|
| Interleukin-12 | 3 | 2024 | 123 | 0.440 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 68 | 0.420 |
Why?
|
| Trans-Activators | 4 | 2002 | 300 | 0.420 |
Why?
|
| Humans | 26 | 2025 | 59366 | 0.410 |
Why?
|
| Th1 Cells | 3 | 2002 | 177 | 0.400 |
Why?
|
| Mice, Knockout | 6 | 2025 | 1997 | 0.390 |
Why?
|
| Animals | 19 | 2025 | 19649 | 0.350 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2003 | 109 | 0.320 |
Why?
|
| Gastroenterologists | 2 | 2019 | 8 | 0.320 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 31 | 0.310 |
Why?
|
| Macrophages | 2 | 2025 | 1015 | 0.310 |
Why?
|
| HIV-1 | 2 | 2025 | 692 | 0.300 |
Why?
|
| Transcription, Genetic | 3 | 2025 | 841 | 0.290 |
Why?
|
| RNA, Antisense | 2 | 2025 | 49 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 10 | 2025 | 3231 | 0.280 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 254 | 0.280 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2017 | 619 | 0.270 |
Why?
|
| Palliative Care | 2 | 2019 | 214 | 0.270 |
Why?
|
| T-Box Domain Proteins | 5 | 2005 | 37 | 0.260 |
Why?
|
| Methyltransferases | 2 | 2017 | 52 | 0.260 |
Why?
|
| RNA, Messenger | 6 | 2017 | 1465 | 0.250 |
Why?
|
| Virus Latency | 1 | 2025 | 29 | 0.240 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2025 | 46 | 0.240 |
Why?
|
| Lipid Droplets | 1 | 2025 | 31 | 0.230 |
Why?
|
| Fibrosis | 2 | 2022 | 153 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 263 | 0.230 |
Why?
|
| Glucokinase | 1 | 2023 | 3 | 0.220 |
Why?
|
| RNA, Viral | 1 | 2025 | 259 | 0.220 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 159 | 0.220 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 53 | 0.220 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 103 | 0.210 |
Why?
|
| Actins | 1 | 2025 | 259 | 0.210 |
Why?
|
| Cell Movement | 1 | 2025 | 428 | 0.210 |
Why?
|
| Male | 6 | 2025 | 27742 | 0.200 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2022 | 13 | 0.200 |
Why?
|
| Ethers | 1 | 2022 | 17 | 0.200 |
Why?
|
| Spiro Compounds | 1 | 2022 | 11 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2022 | 44 | 0.200 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 331 | 0.190 |
Why?
|
| DNA-Binding Proteins | 3 | 2002 | 1151 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2024 | 392 | 0.180 |
Why?
|
| Acid Ceramidase | 1 | 2020 | 1 | 0.180 |
Why?
|
| RNA, Small Interfering | 2 | 2025 | 857 | 0.180 |
Why?
|
| Acetylation | 1 | 2020 | 112 | 0.170 |
Why?
|
| Lysine | 1 | 2020 | 75 | 0.170 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 87 | 0.170 |
Why?
|
| Myoblasts | 1 | 2021 | 63 | 0.170 |
Why?
|
| Protein Domains | 1 | 2020 | 140 | 0.170 |
Why?
|
| Gene Expression | 2 | 2002 | 809 | 0.160 |
Why?
|
| Base Sequence | 4 | 2017 | 1302 | 0.160 |
Why?
|
| Disease Progression | 1 | 2023 | 1119 | 0.160 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 258 | 0.150 |
Why?
|
| Attitude | 1 | 2019 | 96 | 0.150 |
Why?
|
| Half-Life | 2 | 2017 | 75 | 0.150 |
Why?
|
| Advance Care Planning | 1 | 2019 | 61 | 0.150 |
Why?
|
| HIV Infections | 1 | 2025 | 913 | 0.150 |
Why?
|
| Exoribonucleases | 1 | 2017 | 26 | 0.140 |
Why?
|
| Methylation | 1 | 2017 | 124 | 0.140 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2017 | 61 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2053 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2019 | 207 | 0.140 |
Why?
|
| RNA Stability | 1 | 2017 | 97 | 0.130 |
Why?
|
| Gastrulation | 1 | 2016 | 14 | 0.130 |
Why?
|
| Exons | 1 | 2017 | 191 | 0.130 |
Why?
|
| DNA Transposable Elements | 1 | 2017 | 127 | 0.130 |
Why?
|
| Cell Lineage | 5 | 2014 | 259 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 74 | 0.130 |
Why?
|
| Obesity | 1 | 2024 | 1166 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2017 | 89 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 132 | 0.130 |
Why?
|
| Transcription Initiation Site | 1 | 2016 | 49 | 0.130 |
Why?
|
| HeLa Cells | 1 | 2017 | 526 | 0.130 |
Why?
|
| Epigenomics | 1 | 2016 | 54 | 0.130 |
Why?
|
| Organ Specificity | 1 | 2016 | 183 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 398 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 6 | 2003 | 868 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2016 | 245 | 0.120 |
Why?
|
| Computational Biology | 1 | 2017 | 333 | 0.120 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 145 | 0.120 |
Why?
|
| RNA-Binding Proteins | 2 | 2017 | 386 | 0.120 |
Why?
|
| Adenine | 1 | 2014 | 49 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 357 | 0.100 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 101 | 0.100 |
Why?
|
| Receptors, Interleukin-12 | 2 | 2002 | 9 | 0.100 |
Why?
|
| Lymphocyte Activation | 4 | 2003 | 743 | 0.100 |
Why?
|
| Receptors, Interleukin | 2 | 2002 | 39 | 0.100 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 17 | 0.100 |
Why?
|
| MyoD Protein | 1 | 2011 | 44 | 0.090 |
Why?
|
| Antigens, Differentiation | 2 | 2001 | 137 | 0.090 |
Why?
|
| Immunoconjugates | 2 | 2001 | 85 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2005 | 651 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2023 | 411 | 0.080 |
Why?
|
| Female | 4 | 2025 | 30719 | 0.080 |
Why?
|
| Adult | 1 | 2025 | 15679 | 0.070 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2022 | 89 | 0.070 |
Why?
|
| Th2 Cells | 3 | 2003 | 99 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2092 | 0.070 |
Why?
|
| Cell Line | 3 | 2014 | 1983 | 0.070 |
Why?
|
| Immunologic Memory | 2 | 2005 | 283 | 0.060 |
Why?
|
| Virus Activation | 1 | 2025 | 23 | 0.060 |
Why?
|
| GATA3 Transcription Factor | 2 | 2002 | 14 | 0.060 |
Why?
|
| Interleukin-4 | 2 | 2002 | 145 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2024 | 18 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2002 | 271 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 163 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 443 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2001 | 382 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 2380 | 0.050 |
Why?
|
| Nucleosides | 1 | 2022 | 11 | 0.050 |
Why?
|
| Terminal Repeat Sequences | 1 | 2022 | 13 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 1951 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 126 | 0.050 |
Why?
|
| STAT4 Transcription Factor | 1 | 2001 | 7 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2001 | 85 | 0.050 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 15 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 188 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 244 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2516 | 0.050 |
Why?
|
| Cell Fusion | 1 | 2021 | 37 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2025 | 623 | 0.050 |
Why?
|
| Myofibrils | 1 | 2021 | 19 | 0.050 |
Why?
|
| Chickens | 1 | 2021 | 90 | 0.040 |
Why?
|
| Glucose | 1 | 2023 | 445 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 214 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 490 | 0.040 |
Why?
|
| Chromatin | 2 | 2002 | 599 | 0.040 |
Why?
|
| Cell Communication | 1 | 2021 | 124 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 276 | 0.040 |
Why?
|
| Alleles | 1 | 2001 | 411 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2002 | 378 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 365 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2019 | 17 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2019 | 48 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2019 | 47 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 847 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1998 | 20 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 1998 | 32 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 1998 | 42 | 0.040 |
Why?
|
| Lymphokines | 1 | 1998 | 65 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 96 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 750 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7426 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 89 | 0.030 |
Why?
|
| Polyadenylation | 1 | 2016 | 45 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 192 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 405 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 11 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 551 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 545 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2014 | 170 | 0.030 |
Why?
|
| Stem Cells | 1 | 2016 | 255 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2005 | 1206 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 513 | 0.030 |
Why?
|
| Time Factors | 1 | 2019 | 3615 | 0.020 |
Why?
|
| Abatacept | 2 | 2001 | 64 | 0.020 |
Why?
|
| CTLA-4 Antigen | 2 | 2001 | 70 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 941 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2001 | 343 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 1553 | 0.020 |
Why?
|
| Cytokines | 2 | 2003 | 915 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 2456 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2005 | 24 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 71 | 0.020 |
Why?
|
| Granzymes | 1 | 2003 | 18 | 0.010 |
Why?
|
| Arenaviridae Infections | 1 | 2003 | 15 | 0.010 |
Why?
|
| Perforin | 1 | 2003 | 31 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2003 | 34 | 0.010 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2003 | 88 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 147 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 84 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 98 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 1137 | 0.010 |
Why?
|
| CpG Islands | 1 | 2002 | 211 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 293 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 644 | 0.010 |
Why?
|
| Leishmania major | 1 | 2000 | 8 | 0.010 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2000 | 15 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2000 | 23 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 661 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 2000 | 41 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2000 | 105 | 0.010 |
Why?
|
| Cell Death | 1 | 2001 | 271 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 184 | 0.010 |
Why?
|
| Transgenes | 1 | 2000 | 177 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1998 | 19 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 164 | 0.010 |
Why?
|
| Homeostasis | 1 | 2000 | 346 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 450 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 381 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 1998 | 234 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 676 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 394 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 1998 | 197 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 986 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1998 | 474 | 0.010 |
Why?
|
| Melanoma | 1 | 1998 | 318 | 0.010 |
Why?
|